Article Details
Retrieved on: 2024-12-15 04:24:58
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Elevation Oncology's advancement in biopharma by developing EO-1022, an antibody-drug conjugate (ADC) targeting HER3-expressing tumors, in collaboration with Synaffix. It highlights the role of biotechnology and monoclonal antibodies, with references to Synaffix's platform and the PPF Group's subsidiary, Sotio.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here